Full NCBI bibliography Martin D. Berger
berger md - Search Results - PubMed (nih.gov)
A Selection of publications:
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz HJ, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry WS, Hsiehchen D, Macarulla T, Tabernero J, Pichler R, Khushman M, Manne U, Lou E, Wolf D, Sokolova V, Schnaiter S, Zeimet AG, Gulhati P, Widmann G, Seeber A. NPJ Precis Oncol. 2023 Jul 3;7(1):64
The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook. Tran LC, Özdemir BC, Berger MD. Pharmaceuticals. 2023 Oct 4;16(10):1411
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Puccini A, Seeber A, Berger MD.Cancers (Basel). 2022 Oct 3;14(19):4828
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Puccini A, Poorman K, Catalano F, Seeber A, Goldberg RM, Salem ME, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Philip PA, Marshall JL, Korn WM, Lenz HJ. Oncogene. 2022 Jun;41(26):3455-3460
Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer. Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Hon Lim K, San Tan G, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ. Clin Cancer Res. 2022 May 2;28(9):1863-1870
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Puccini A, Seeber A, Xiu J, Goldberg RM, Soldato D, Grothey A, Shields AF, Salem ME, Battaglin F, Berger MD, El-Deiry WS, Togunaka R, Naseem M, Zhang W, Arora SP, Khushman MM, Hall MJ, Philip PA, Marshall JL, Korn WM, Lenz HJ. NPJ Precis Oncol. 2021 Oct 27;5(1):95
Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont? Wenning AS, Ryser CO, Andreou A, Gloor B, Berger MD. Schweiz. Gastroenterol. 2021 Oct 15: 138-147
LAG-3 expression predicts outcome in stage II colon cancer. Ryner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galvan JA, Lugli A, Zlobec I, Berger MD. J Pers Med. 2021 Jul 30;11(8):749
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Naseem M, Cao S, Yang D, Millstein J, Puccini A, Loupakis F, Stintzing S, Cremolini C, Tokunaga R, Battaglin F, Soni S, Berger MD, Barzi A, Zhang W, Falcone A, Heinemann V, Lenz HJ. SciRep. 2021 Jun 9;11(1):12191
CCR5 is a potential therapeutic target for cancer. Hemmatazad H, Berger MD. Expert Opin Ther Targets. 2021 Apr;25(4):311-327
Tumour budding in solid cancers. Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Nat Rev Clin Oncol. 2021 Feb;18(2):101-115
The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Naseem M, Puccini A, Berger MD, Soni S, Zhang W, Chen S, Hwang JJ,Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. Eur J Cancer. 2020 Nov;140:119-129
Multicenter international society for immunotherapy of cancer study of the consensus Immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, LeeJJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S,Grützmann R, Van den Eynde M, Jouret Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P,Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Bruni D, Lanzi A, El Sissy C, Haicheur N,Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S,Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T,Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Fox BA, Pagès F, Galon J. J Clin Oncol. 2020 Nov 1;38(31):3638-3651
Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Togunaka R,Naseem M, Barzi A, Iqbal S, Zhang W, Soni S, Hwang JJ, Philip PA, Sciallero S, Korn WM, Marshall JL, Lenz HJ. Clin Cancer Res. 2020 Nov 15;26(22):5943-5951
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. Eur J Cancer. 2020 May;131:89-97
Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. Cancer Sci. 2020 Feb;111(2):441-450
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. Int J Cancer. 2019 Oct 15;145(8):2082-2090
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. Eur J Cancer. 2019 Apr;111:138-147
Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. Clin Cancer Res. 2019 May 15;25(10):3096-3103
Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Eur J Cancer. 2019 Jan;107:100-114
Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. Int J Cancer. 2019 May 15;144(10):2567-2577
Stromal PD-1/PD-L1 expression predicts outcome in colon cancer patients. Wyss J, Dislich B, Koelzer VH, Galvan JA, Dawson H, Hadrich M, Inderbitzin D, Lugli A, Zlobec I, Berger MD. Clin Colorectal Cancer. 2019 Mar;18(1):e20-e38
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. Lancet. 2018 May 26;391(10135):2128-2139
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y,Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. Clin Cancer Res. 2018 Feb 15;24(4):784-793
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ. Ann Oncol. 2017 Nov 1;28(11):2780-2785
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. Ann Oncol May 28(5):1015-1022.
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. Eur J Cancer. 2017 May;77:13-20
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Pharmacogenomics J. 2017 Jan;17(1):36-41
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamoto Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Clin Cancer Res. 2016 Jul 1;22(13):3218-26
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellvi-Bel S, Munoz J, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN. Lancet Gastroenterol Hepatol 2016 Nov;1(3):207-216
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Ann Oncol. 2015 Dec;26(12):2450-6
Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Mol Cancer Ther. 2015 Oct;14(10):2401-8
